Key Highlights
- Kevin Krause named as President and CEO of ArrePath.
- Brings 25+ years of biotech experience, including leadership roles at AN2 Therapeutics and Achaogen.
- Focuses on advancing ArrePath’s pipeline of anti-infectives using AI/ML technology.
Source: Business Wire
Notable Quotes
- “We are thrilled to welcome Kevin as the new Chief Executive Officer of ArrePath. Thanks to his exceptional track record of visionary leadership, we are confident that Kevin will use the team’s momentum to advance their lead program to the clinic and unlock new opportunities for growth.” — Dr. Zemer Gitai, co-founder at ArrePath
- “I am honored to join ArrePath, which has made tremendous progress on the application of its proprietary AI/ML platform to discover antibacterials with novel mechanisms of action.” — Kevin Krause, President and CEO at ArrePath
SoHC's Take
Kevin Krause’s appointment as CEO marks a pivotal moment for ArrePath as it expands its focus on AI/ML-driven discovery of anti-infectives. With Krause’s extensive background in clinical development and his success with several FDA-approved therapies, ArrePath is well-positioned to tackle the pressing global challenge of antimicrobial resistance (AMR). His proven leadership and deep expertise in the biotech sector will undoubtedly accelerate the company’s mission to deliver innovative solutions to combat infectious diseases.
